Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive
This article was originally published in The Pink Sheet Daily
Executive Summary
However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.
You may also be interested in...
Merck's Ezetimibe Faces Reimbursement Threat In Europe
Results from the ENHANCE and ARBITER 6-HALTS trials may finally mean reduced coverage in Germany and the U.K.
Merck's Ezetimibe Faces Reimbursement Threat In Europe
Results from the ENHANCE and ARBITER 6-HALTS trials may finally mean reduced coverage in Germany and the U.K.
Merck Still Plans Big Cost Savings This Year From Schering-Plough Deal
In his first public appearance since completing the acquisition last November of Schering-Plough, Merck chief executive Richard Clark told an investor conference that roughly half of the projected savings from the merger can be realized this year